AAHRPP Accredits Four More Research Organizations
WASHINGTON, D.C.âThe Association for the Accreditation of Human Research Protection Programs today announced that it has accredited four more research organizations-one each in the U.S., Canada, Korea, and Taiwan.
The newly accredited organizations are:
- BC Diabetes, Vancouver, British Columbia, Canada
- Boston Medical Center and Boston University Medical Campus, Boston, Massachusetts
- Chang Gung Medical Foundation, Taipei City, Taiwan
- Korea University Medical Center, Seoul, Korea
They join 18 other organizations in earning AAHRPP accreditation this year, bringing the total to 22 in 2017 and 251 accredited organizations overall. Of those, 49 are outside the U.S.
“This was a good year for AAHRPP accreditation and for the research participants that AAHRPP’s high standards help protect,” AAHRPP President and CEO Elyse I. Summers said.
“AAHRPP accreditation has long been recognized as the gold standard for research protections and as evidence of an organization’s commitment to high-quality, ethical research,” she added. “In an increasingly collaborative research enterprise, accreditation is more valuable than ever because it signals that an organization is a trusted partner.”
To earn accreditation, organizations must show that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research.
AAHRPP has accredited organizations across the United States and in Belgium, Brazil, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, South Africa, Taiwan and Thailand.
All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, 70 percent of U.S. medical colleges and 84 percent of the top National Institute of Health-funded academic medical centers are either AAHRPP accredited or have begun the accreditation process. NIH, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
About AAHRPP:
A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit www.aahrpp.org.
###
FOR MORE INFORMATION CONTACT:
Sarah Kiskaddon
Vice President, Global Development and Public Affairs
skiskaddon@aahrpp.org
(202) 783-1112
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
